Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
Long-term or high-dose L-DOPA therapy in patients with Parkinson's disease (PD) may accelerate degeneration of dopaminergic neurons, possibly by increasing oxidative stress. To investigate the effects of cabergoline on peroxynitrite-mediated oxidative damage caused by L-DOPA, the concentration of 3-nitrotyrosine in cerebrospinal fluid (CSF) of 18 PD patients was compared with that in 20 normal controls. The concentration of 3-nitrotyrosine in patients following L-DOPA therapy was significantly higher than in untreated PD patients and controls. On the other hand, the concentration in PD patients after cabergoline therapy was significantly lower than in PD patients after L-DOPA therapy alone. These data suggest that cabergoline scavenges peroxynitrite induced by L-DOPA in patients with PD.
Isobe
C
C
Department of Neurology, Iwate Medical University, Morioka, Iwate, Japan. chiso@apost.plala.or.jp
Abe
T
T
Kikuchi
T
T
Murata
T
T
Sato
C
C
Terayama
Y
Y
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D002851:Chromatography, High Pressure Liquid; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D030421:Peroxynitrous Acid / Q000378:metabolism*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid / Q000187:drug effects
D000978:Antiparkinson Agents; D004873:Ergolines; D016166:Free Radical Scavengers; D030421:Peroxynitrous Acid; C002744:3-nitrotyrosine; D014443:Tyrosine; D007980:Levodopa; D000077465:Cabergoline